Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
First Claim
1. A method of treating or delaying the onset of an malignancy-associated disorder, said method comprising administering to a subject in need thereof an antibody to the polypeptide selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO;
4 in an amount sufficient to treat or prevent said malignancy-associated disorder in said subject.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides human chronic myelocytic leukemia-like proteins (CML protein) and isolated nucleic acid molecules encoding the same. Also provided are antibodies that immunospecifically-bind to CML polypeptides or polynucleotides, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which CML polypeptides, polynucleotides, and antibodies are used in the detection, prevention, and treatment of a broad range of pathological states, and methods of treating malignancy-related disorders by modulating activity or expression of CML proteins.
-
Citations
43 Claims
-
1. A method of treating or delaying the onset of an malignancy-associated disorder, said method comprising administering to a subject in need thereof an antibody to the polypeptide selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO;
4 in an amount sufficient to treat or prevent said malignancy-associated disorder in said subject. - View Dependent Claims (2, 3, 4)
- 2 and SEQ ID NO;
-
5. A method for determining the presence of or predisposition to a disease associated with altered levels of SEQ ID NO:
- 2 or SEQ ID NO;
4 in a first mammalian subject, said method comprising;
(a) providing a protein sample from said first mammalian subject;
(b) providing a control protein sample from a second mammalian subject known not to have or be predisposed to said disease;
(c) measuring the amount of SEQ ID NO;
2 or SEQ ID NO;
4 polypeptide in said subject sample; and
(d) comparing the amount of SEQ ID NO;
2 or SEQ ID NO;
4 polypeptide in said subject protein sample to the amount of SEQ ID NO;
2 or SEQ ID NO;
4 polypeptide in said control protein sample,wherein an alteration in the expression level of the SEQ ID NO;
2 or SEQ ID NO;
4 polypeptide in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.
- 2 or SEQ ID NO;
-
6. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid of SEQ ID NO:
- 1 or SEQ ID NO;
3 in a first mammalian subject, said method comprising;
(a) providing a nucleic acid sample from said first mammalian subject;
(b) providing a control nucleic acid sample from a second mammalian subject known not to have or be predisposed to said disease;
(c) measuring the amount of SEQ ID NO;
1 or SEQ ID NO;
3 in said subject sample; and
(d) comparing the amount of SEQ ID NO;
1 or SEQ ID NO;
3 in said subject nucleic acid sample to the amount of SEQ ID NO;
1 or SEQ ID NO;
3 in said control nucleic acid sample,wherein an alteration in the expression level of SEQ ID NO;
1 or SEQ ID NO;
3 in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.
- 1 or SEQ ID NO;
-
7. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a SEQ ID NO:
- 2 or SEQ ID NO;
4 polypeptide in an amount sufficient to alleviate the pathological state, wherein the polypeptide has an amino acid sequence at least 95% identical to the SEQ ID NO;
2 or SEQ ID NO;
4 polypeptide, or a biologically active fragment thereof
- 2 or SEQ ID NO;
-
8. A method of treating a pathological state in a mammal, the method comprising administering to the mammal an antibody to a SEQ ID NO:
- 2 or SEQ ID NO;
4 polypeptide in an amount sufficient to alleviate the pathological state. - View Dependent Claims (9, 10)
- 2 or SEQ ID NO;
-
11. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
-
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting SEQ ID NOS;
2 and 4; and
(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence. - View Dependent Claims (12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)
-
-
15. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
-
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting of SEQ ID NOS;
2 and 4;
(d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS;
2 and 4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS;
2 and 4, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
-
Specification